Tiagabine Hydrochloride Tablet, Film Coated
Product Images NDC 62756-224

7 FDA label images from Sun Pharmaceutical Industries, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tiagabine Hydrochloride (NDC 62756-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of Tiagabine Hydrochloride, showing the detailed arrangement of sulfur-containing rings, a piperidine ring with a carboxylic acid group, and the hydrochloride salt form.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing the percentage reduction in partial seizure rate among patients taking Tiagabine Hydrochloride 32 + 56 mg/day versus placebo. The x-axis represents the percentage of patients, while the y-axis shows the percentage reduction in partial seizure rate, ranging from -250% to 100%. The graph indicates improvement and worsening trends for both treatment groups.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A cumulative distribution graph showing percentage reduction in partial seizure rate on the vertical axis versus percentage of patients on the horizontal axis, comparing Tiagabine Hydrochloride at doses of 16 mg/day, 32 mg/day, and 56 mg/day against placebo. The graph indicates patient response variability, with curves illustrating relative improvement or worsening in seizure rates for each treatment group.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph comparing the percentage reduction in partial seizure rate among patients treated with placebo, Tiagabine Hydrochloride 8 mg QID, and Tiagabine Hydrochloride 16 mg BID. The x-axis represents the cumulative percentage of patients, while the y-axis shows the percentage reduction in partial seizure rate, indicating improvement or worsening.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A cumulative distribution plot comparing the percentage reduction in partial seizure rate between patients treated with Tiagabine Hydrochloride 10 mg TID and a placebo group. The y-axis shows percentage reduction from -250% to 100%, and the x-axis shows the percentage of patients from 0 to 100%. Arrows indicate improvement above 0% and worsening below 0% reduction.*
FDA Label Image

Tiagabin-label-2mg (Tiagabine Label 2mg)

Tiagabin-label-2mg (Tiagabine Label 2mg)
Label for Tiagabine Hydrochloride Tablets, 2 mg film-coated oral tablets, with a package size of 30 tablets. The label shows the product name, strength, labeler Sun Pharmaceutical Industries, Inc., and manufacturer Sun Pharmaceutical Ind. Ltd. Additional information includes storage conditions and dispensing instructions for pharmacists.*
FDA Label Image

Tiagabine-label-4mg (Tiagabine Label 4mg)

Tiagabine-label-4mg (Tiagabine Label 4mg)
Label for Tiagabine Hydrochloride Tablets 4 mg film-coated tablets. The label includes dosage strength, instructions for pharmacists, storage conditions, and distributor/manufacturer information. The product is labeled by Sun Pharmaceutical Industries, Inc. and Sun Pharmaceutical Ind. Ltd., India, with a package size of 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.